

COMMONWEALTH OF PENNSYLVANIA
DEPARTMENT OF STATE
BUREAU OF PROFESSIONAL AND OCCUPATIONAL AFFAIRS

F I N A L M I N U T E S

MEETING OF:

STATE BOARD OF PHARMACY

TIME: 10:30 A.M.

Held at

PENNSYLVANIA DEPARTMENT OF STATE

2525 North 7th Street

CoPA HUB, Eaton Conference Room

Harrisburg, Pennsylvania 17110

as well as

VIA MICROSOFT TEAMS

August 25, 2026

State Board of Pharmacy
August 25, 2026

BOARD MEMBERS:

Christine Roussel, Pharm.D., BCOP, BCSCP, Chairperson
Arion R. Claggett, Acting Commissioner of
Professional and Occupational Affairs
Eric Esterbrook, R.Ph., Vice Chairperson
Janet Getzey Hart, R.Ph., Secretary
James Reed Jr., R.Ph.
John R. Slagle, R.Ph. - Absent
Yasmin Mukhtar, Office of Attorney General

BUREAU PERSONNEL:

Sean C. Barrett, Esquire, Board Counsel
Nathan C. Giunta, Esquire, Board Prosecution Liaison
Marc Farrell, Esquire, Regulatory Counsel, Office of
Chief Counsel
Ray J. Michalowski, Esquire, Senior Board Prosecutor
and Prosecution Liaison
Ashley P. Murphy, Esquire, Board Prosecution Liaison
Jonathan Blake, Esquire, Board Prosecutor
Caroline Bailey, Esquire, Board Prosecutor
Sara Trimmer, Pharm.D., R.Ph., Executive Secretary
Willow Marsh, Legislative Aide, Office of Legislative
Affairs
Cory Ulisse, Pharm.D., Drug Program Specialist
Jessica Zukoski, Senior Legal Analyst
Jason Giurintano, Esquire, Deputy Chief Counsel,
Counsel Division
Andrew LaFratte, MPA, Deputy Policy Director, Office
of Policy
Carolyn A. DeLaurentis, Esquire, Chief Counsel,
Office of Chief Counsel
Danie Bendesky, Special Assistant for Strategic
Initiatives
Ronald Rouse, Esquire, Senior Counsel, Office of
General Counsel
Shana Walter, Esquire, Deputy Chief Counsel,
Prosecution Division
Julie Drodody, Program Co-Manager, Professional Health
Monitoring Program
Steven Zahn, Pharmacy Inspector, Bureau of
Enforcement and Investigation

State Board of Pharmacy
August 25, 2026

ALSO PRESENT:

Muneeza Iqbal, Deputy Secretary of Health Resources
and Sciences, Pennsylvania Department of Health
Lindsey Walsh, Executive Advisor to the Deputy
Secretary of Health Resources and Services,
Pennsylvania Department of Health
Beth Conrad, Human Resource Manager, Department of
State
Nicole Campbell, Division Chief, Division of Law
Enforcement Education and Trade Schools,
Pennsylvania Department of Education
Jennifer A. Sullivan, Pharm.D., CPPS, Pharmacy
Manager of Quality, WellSpan York Hospital
Terry Talbott, RPh., Pharmacy Advocate and Regulatory
Consultant, Founder, PraeScriptum Advisors
Michelle Mikus, Pharm.D., ConnectiveRX
Misha Patel, Esquire, Government Relations
Specialist, Pennsylvania Medical Society
Christopher Miller, Pharm.D., Director, Pharmacy
Quality and Compliance, Giant Eagle Inc.
Brittany Venturella, Pharm.D., CSP, Manager of
Clinical Specialty and Central Fill Pharmacy
Catherine Navagh, Pharm.D., RPh - REMS, ConnectiveRX
Victoria Elliott, R.Ph., CEO, Pennsylvania
Pharmacists Association
Lisa Braccini-Barletta, MBA, R.Ph., Director of
Pharmacy, Penn State Milton S. Hershey Medical
Center
Trisha Miller, Pharm.D., MPH, BCACP, Ambulatory Care
& Public Health Pharmacy Leader, UPMC
Ed Foote, Pharm.D., FCCP, Dean, Philadelphia College
of Pharmacy, Saint Joseph's University
Susan DelMonico, R.Ph., JD, Associate General
Counsel, Deputy, Deputy Pharmacy Compliance
Officer, Genoa Healthcare
Navid Hojatti, Pharm.D., Lead Director, Pharmacy
Advocacy and Regulatory Affairs, CVS Health
Nicole Fidler, Associate, Malady & Wooten Inc.
Rylee Swails, Associate, Malady & Wooten Inc.
Amanda McKibben, PANTHERx Rare Pharmacy
Jennifer Raibley, Pharm.D., Divisional Pharmacy
Manager, Albertsons Companies
Wesley Rish, Attorney, Rish Law Office LLC
Jennifer Hall, CAPS Pharmacy
Charlotte Harris, Emerus

State Board of Pharmacy
August 25, 2026

ALSO PRESENT: (cont.)

Alexander Meligakes, Pharm.D., Wellspan Health
Missy Wigley, Public Policy and Data Manager,
Alliance for Pharmacy Compounding
Amanda Abernathy, Program Manager, Pharmacy
Technician Training, UPMC
Natalie Percival, Pharm.D., TTS, Assistant Professor
of Pharmacy Practice, Wilkes University Nesbitt
School of Pharmacy
Joshua Finger, Pharm.D., Dragonfly Health
John Nawrocki, Pharmacy Manager, Symbria Rx Services
Jared Bruce, Senior Associate, Dinsmore
Donna Watson, Pharm.D., R.Ph., DICVP, FSVHP, Director
of Pharmacy Services, Ryan Veterinary Hospital,
PennVet
Jamie Ksiazek, Pharm.D., Pentec Health
Deanne Lynn Hall, Pharm.D., Associate Director of
Experiential Learning, Associate Professor of
Pharmacy, University of Pittsburgh School of
Pharmacy
Gregg Hoolahan, Pharmacy Manager, Symbria Rx Services
Olivia Sugarman, PhD, MPH, Assistant Scientist, Johns
Hopkins University Bloomberg School of Public
Health
Zayne A. Kemler, Paralegal, Government Relations,
Myers Brier & Kelly LLP
Dawn M. Mowery, Certified Pharmacy Technician, Penn
Medicine, University of Pennsylvania Health System
Tracy Pugh, Knowledge Management Director, Vital
Strategies
Sheetal Kamath
Sarah Derr, Pharm.D., MPS, State Regulatory Affairs
Director, Alliance for Pharmacy Compounding
Michael H. Cardosi, Pentec Health
Lisa Scannapieco, Vice President of Corporate and
Regulatory Compliance, Pentec Health
Donald Styer, Attorney, Styer Law LLC
Amy Piorkowski, Director of Pharmacy, Central
Admixture Pharmacy Services Inc.
Jennifer Binggeli, Pharm.D., JD, MBA, BCPS, CHC,
Senior Pharmacy Compliance Manager, Chewy
Amy Lynn Seybert, Pharm.D., FASHP, FCCP, CHSE, Dean,
Dr. Gordan J. Vanscoy Endowed Chair of Pharmacy,
University of Pittsburgh School of Pharmacy

State Board of Pharmacy
August 25, 2026

ALSO PRESENT: (cont.)

Genevieve Levans, Senior Director of Pharmacy, Penn
Medicine, University of Pennsylvania Health System
Heather King, Manager of Pharmacy Programs and
Compliance, Pharmacy Compliance Officer, Northeast
Shared Services
Traci Collier, Pharm.D., Director of Regulatory
Affairs, Olympia Pharmaceuticals and Wesley
Pharmaceuticals
Jonathan Ference, Pharm.D., Dean, Nesbitt School of
Pharmacy, Wilkes University
Katie Gruber, MSW, CADC, Billing Data and Training
Manager, Peer Assistance Monitoring Program
Daniel Longyhore, Pharm.D., Ed.D., Geisinger Health
Mayank Amin, Pharm.D., R.Ph., Owner, Skipjack
Pharmacy
Regan Ceraso, RPh, Director of Quality and
Compliance, Grane Rx
Rhonda Thomas, Pharm.D., MBA, BCPS, BCSCP,
Administrator of Pharmacy Services, Jefferson,
Treasurer, Pennsylvania Society of Health-System
Pharmacists
Jill Rebuck, Executive Director, Pennsylvania Society
of Health-System Pharmacists
Caroline O'Brien, CPhT-Adv, CVOP, Technician, Board
Member, Pennsylvania Society of Health-System
Pharmacists
Scott Young, Policy Specialist, Company Owner, Summit
Policy
Derek Knouse, Pharm.D., District Leader, CVS Health
Lily Phung, Pharm.D.
Matthew Popowicz, Cardinal Health
George Dennis, API Student, Duquesne University
Sosa
Jennifer
Call In # 1-973-634-0699
Call In # 1-717-875-1056
Call In # 1-724-622-3760
Laurie Elliott, Sargent's Court Reporting Service,
Inc.

State Board of Pharmacy

August 25, 2026

The scheduled meeting of the State Board of Pharmacy was held on Tuesday, August 25, 2025. Christine Roussel, Pharm.D., BCOP, BCSCP, Chairperson called the meeting to order at 10:32 a.m.

[Pursuant to Section 708(a)(5) of the Sunshine Act, at 9:00 a.m., the Board entered into Executive Session with Sean C. Barrett, Esquire, Board Counsel, for the purpose of conducting quasi-judicial deliberations and to receive the advice of Board Counsel. The Board returned to open session at 10:30 a.m.]

[Sean C. Barrett, Esquire, Board Counsel, noted the pharmacy meeting was being recorded, and those who continued to participate were giving their consent to be recorded.

Mr. Barrett also noted, at 9:00 a.m., the Board entered into Executive Session for the purpose of conducting quasi-judicial deliberations on a number of matters and to receive the advice of counsel.]

Introduction of Board Members/Attendees

[Christine Roussel, Pharm.D., BCOP, BCSCP,
Chairperson, requested an introduction of Board
members and attendees. A quorum was present.]

Approval of Minutes

CHAIR ROUSSEL:

Okay. So first, let's do the approval
of the minutes. We have the minutes
from our June 11th meeting, 2026. And
then we also have the June 23, 2026.

Any discussion, any edits that
needed to be made to either of those
minutes? Any further discussion?

All right. Do we want any motions
around those minutes?

MR. ESTERBROOK:

I'll make a motion to approve the
minutes, Esterbrook.

CHAIR ROUSSEL:

Thank you.

MR. REED:

Reed, second.

CHAIR ROUSSEL:

1 Okay. Any further discussion? No
2 edits, okay. Motion to approve the
3 minutes from June 1th and June 23rd of
4 2026.

5 We'll call the vote.

6
7 Reed, aye; Hart, aye; Esterbrook, aye;
8 Claggett, aye; Mukhtar, aye; Roussel,
9 aye.

10 [The motion carried unanimously.]

11 ***

12 Report of Board Prosecution

13 [Ashley P. Murphy, Esquire, Board Prosecution Liaison
14 presented the Consent Agreements for Agenda Item No.
15 4, Case No. 23-54-010105; and Agenda Item No. 5, Case
16 No. 24-54-018893.]

17 MR. BARRETT:

18 Based on the report of Prosecution, I
19 believe the Board Chair would entertain
20 a motion to approve the Consent
21 Agreement at Case No. 23-54-010105.
22 And I will note for the record that
23 Board Member Hart recused herself from
24 the deliberations on this matter.

25 CHAIR ROUSSEL:

1 No further discussions. Let's call the
2 vote.

3 ACTING COMMISSIONER CLAGGETT:

4 We have to ask for a motion.

5 CHAIR ROUSSEL:

6 Oh, sorry, you're right.

7 ACTING COMMISSIONER CLAGGETT:

8 Claggett, so moved.

9 CHAIR ROUSSEL:

10 Yes, I got excited.

11 MR. REED:

12 Reed, second.

13 CHAIR ROUSSEL:

14 Any further discussion? No? Let's
15 call the vote.

16

17 Reed, aye; Hart, recuse; Esterbrook,
18 aye; Claggett, aye; Mukhtar, aye;
19 Roussel, aye.

20 [The motion carried. Ms. Hart was recused from
21 deliberations and voting on the motion. The
22 Respondent at Agenda Item No. 4, Case No. 23-54-
23 010105, is Robin E. Stewart-Adams, RPh.]

24 ***

25 MR. BARRETT:

1 Based on Executive Session
2 deliberations, at Item No. 5, Case No.
3 24-54-018893, I believe the Board Chair
4 would entertain a motion to approve the
5 Consent Agreement at that number.

6 ACTING COMMISSIONER CLAGGETT:

7 Claggett, so moved.

8 MR. REED:

9 Reed, second.

10 CHAIR ROUSSEL:

11 Any further discussion? No further
12 discussions? Let's call the vote.

13

14 Reed, aye; Hart, aye; Esterbrook, aye;
15 Claggett, aye; Mukhtar, aye; Roussel,
16 aye.

17 [The motion carried unanimously. The Respondent at
18 Agenda Item No. 5, Case No. 23-54-018893, is RGH
19 Enterprises, LLC d/b/a Edgepark Medical Supplies;
20 Cardinal Health at Home.]

21 ***

22 Appointment - Survey of Pharmacists' Experiences with
23 Buprenorphine Dispensing Policies

24 [Olivia Sugarman, PhD, MPH, Assistant Scientist,
25 Johns Hopkins University Bloomberg School of Public

1 Health, presented results from a survey of
2 pharmacists regarding their experiences with
3 buprenorphine dispensing policies. She noted the
4 survey was funded by the Bloomberg Overdose
5 Prevention Initiative. In addition, she noted her
6 department was part of a multi-state campaign funded
7 by Bloomberg Philanthropies with a goal of reducing
8 overdoses in seven states.

9 Dr. Sugarman provided context for the survey,
10 noting buprenorphine is the gold standard treatment
11 for opioid use disorders and is incredibly effective
12 at reducing overdose risk and improving recovery
13 outcomes. However, she also noted the scope of
14 practice around buprenorphine changed recently from
15 the removal of the X waiver, state programs, and
16 practices to increase prescribing at large. She
17 pointed out pharmacies are feeling more of the
18 changes over time. The survey was conducted with the
19 ultimate goal of understanding how pharmacists
20 experience or view buprenorphine for opioid use
21 disorder and what pharmacies are doing around
22 stocking and dispensing policies.

23 Dr. Sugarman shared the requirements for who
24 could participate in the survey. She also noted the
25 survey was completed between mid-February 2026 and

1 mid-March 2026. She stated the results are still
2 fresh, and her department is in the middle of the
3 analysis. She also shared statistics on who in
4 Pennsylvania responded to the survey.

5 Questions asked were about general stocking and
6 dispensing practices where the respondents worked.
7 She noted 94 percent of pharmacists stated their
8 pharmacy keeps buprenorphine products in stock. When
9 asked about the type of products carried, generics
10 were popular. Dr. Sugarman shared additional
11 questions regarding the average number of
12 buprenorphine prescriptions were asked with 30
13 percent of respondents noting their pharmacy fills an
14 average of 21 or more prescriptions per week.
15 Additionally, most people stated they were filling
16 about the same amount of buprenorphine compared to
17 the prior year. 41 percent were filling more
18 prescriptions, and only six percent were filling
19 less.

20 Regarding pharmacy level dispensing policies, Dr.
21 Sugarman reported 92 percent of pharmacies had a
22 policy about no early refill dates. Additional
23 policies mentioned included locality of patients or
24 prescribers, dosage range, telemedicine, and ID
25 requirements. She noted the survey delve deeper into

1 policies for no early refill dates and dosage range.
2 She shared the survey asked a combination of closed-
3 ended questions and open-ended questions. She
4 presented quotes people offered about existing
5 policies that made it easier or more difficult to
6 fill buprenorphine prescriptions.

7 Dr. Sugarman stated the survey next reviewed
8 refusals and barriers. Most pharmacists shared they
9 rarely declined to dispense buprenorphine. Reasons
10 were most often consistent with pharmacy policies.
11 The survey also ranked barriers to dispensing and
12 stocking on a Likert scale. The top barriers were
13 noted as the ability to communicate directly with
14 prescribers, concerns about DEA investigations, and
15 ordering thresholds. Additional questions concerned
16 ordering thresholds.

17 When asked about proposed strategies or
18 hypothetical policies to close gaps at the pharmacy
19 level, most pharmacists were nonchalant in their
20 responses. However, pharmacists were largely in
21 support of changes by wholesale distributors.
22 Additional open-ended responses shared pharmacists'
23 opinions on what guidance and resources would be
24 helpful to understanding ordering thresholds for
25 buprenorphine products.

1 The final question gave an option to have an open
2 space to note anything that should be known about
3 buprenorphine dispensing in general. She provided a
4 brief summary of responses. She highlighted one
5 comment that shared pharmacies were in a difficult
6 position, balancing the needs of the public while
7 being expected to curb the opioid use epidemic.

8 Dr. Sugarman addressed the limitations of the
9 survey. She concluded by summarizing major takeaways
10 from the survey.

11 Mr. Reed thanked Dr. Sugarman for the information
12 presented. He commented on challenges that included
13 stigma in regards to patients using buprenorphine,
14 thresholds, and pharmacy closures.

15 Chair Roussel echoed Mr. Reed's comments,
16 emphasizing access challenges. She acknowledged
17 access is outside the Board's scope but was important
18 for legislators to identify. She enjoyed hearing
19 about the percentage of pharmacies providing long-
20 acting Suboxone.

21 Mr. Esterbrook shared he heard, when a pharmacy
22 reaches a threshold with a wholesaler, the wholesaler
23 reports the order to the DEA as suspicious. He
24 noted, if the policy existed, it should be addressed
25 with wholesalers. Mr. Reed commented, as more people

1 look for treatments for opioid use disorder, demand
2 would rise, and thresholds needed to be increased in
3 the right manner.

4 Muneeza Iqbal, Deputy Secretary of Health
5 Resources and Sciences, Pennsylvania Department of
6 Health, shared presenting two years ago on the topic
7 of buprenorphine dispensing. During listening
8 sessions with pharmacists, she also spoke with some
9 pharmaceutical wholesalers. She stated the
10 wholesalers did not like to make their process for
11 setting thresholds publicly known; however, her
12 understanding was the thresholds were set by
13 reviewing the historic ordering numbers. She
14 questioned how historic numbers could be used in
15 light of pharmacy closures. She added wholesalers
16 stated their process for increasing ordering
17 thresholds was easy and should be utilized by
18 pharmacists. Meanwhile, pharmacists shared that the
19 process was complicated and often unaware of when
20 they were close to hitting their threshold.

21 Mr. Barrett commented Pennsylvania is in an
22 interesting position as the state does not regulate
23 manufacturers and wholesalers the same way as other
24 states.

25 Chair Roussel commented the new Drugs, Devices,

1 and Cosmetics Board under the Department of Health
2 would be a place for Dr. Sugarman's presentation.
3 Ms. Iqbal agreed with Chair Roussel, noting she would
4 recommend the suggestion to the Secretary of Health.

5 Victoria Elliott, R.Ph., CEO, Pennsylvania
6 Pharmacists Association (PPA), noted PPA was privy to
7 the survey report and was working on an advocacy
8 plan. She also stated PPA was working on finalizing
9 programs for their annual conference, but she hoped a
10 session could be offered on the subject at the
11 conference. Chair Roussel commented education on how
12 to request to have limits raised would be helpful.

13 Chair Roussel noted buprenorphine is life saving
14 for the patients who need it. She extended
15 appreciation for a great appointment.]

16 ***

17 Report of Prosecution (cont.)

18 [Nathan C. Giunta, Esquire, Board Prosecution
19 Liaison, presented the Consent Agreements for Agenda
20 Item No. 6, Case No. 23-54-015900; Agenda No. 7, Case
21 No. 25-54-009263; Agenda Item No. 8. Case No. 25-54-
22 015364; and Agenda Item No. 9, Case Nos. 26-54-000752
23 and 26-54-001677. Wesley Rish, Esquire, Rish Law
24 Office LLC, offered statements on behalf of his
25 client at Agenda Item No. 6.]

[Ray J. Michalowski, Esquire, Senior Board Prosecutor and Prosecution Liaison, presented the VRP Consent Agreement for Agenda Item No. 10, Case No. 26-54-012271.]

[After discussion, the Board noted it would reenter Executive Session at the end of the meeting prior to voting on Agenda Items 6 through 9.]

MR. BARRETT:

Okay. So Item No. 10, based on Executive Session deliberations and the Report of Prosecution, I believe the Board Chair would entertain a motion to approve the Consent Agreement at Case No. 26-54-012271.

CHAIR ROUSSEL:

Any motions?

ACTING COMMISSIONER CLAGGETT:

Claggett, so moved.

MR. REED:

Reed, second.

CHAIR ROUSSEL:

Any further discussion? Let's call the

1 vote.

2

3 Reed, aye; Hart, aye; Esterbrook, aye;
4 Claggett, aye; Mukhtar, aye; Roussel,
5 aye.

6 [The motion carried unanimously.]

7

8 Report of Board Counsel

9 MR. BARRETT:

10 Based on Executive Session
11 deliberations, at Item No. 11, I
12 believe the Board Chari would entertain
13 a motion to approve the Final
14 Adjudication and Order at Case No. 25-
15 54-016082, Beta Patel, RPh.

16 CHAIR ROUSSEL:

17 Yes, I would entertain a motion.

18 ACTING COMMISSIONER CLAGGETT:

19 Claggett, so moved.

20 MR. REED:

21 Reed, second.

22 CHAIR ROUSSEL:

23 Any further discussion? We'll call the
24 vote.

25

1 Reed, aye; Hart, aye; Esterbrook, aye;
2 Claggett, aye; Mukhtar, aye; Roussel,
3 aye.

4 [The motion carried unanimously.]

5 ***

6 MR. BARRETT:

7 Okay, and at Item No. 12, based upon
8 information provided by the Applicant
9 and discussion in Executive Session, I
10 believe the Board Chair would entertain
11 a motion to rescind the provisional
12 denial at HRx Pharmacy, Case No. 25-54-
13 015851.

14 CHAIR ROUSSEL:

15 Any motions?

16 ACTING COMMISSIONER CLAGGETT:

17 Claggett, so moved.

18 MR. REED:

19 Reed, second.

20 CHAIR ROUSSEL:

21 Any further discussion? We'll call the
22 vote.

23

24 Reed, aye; Hart, aye; Esterbrook, aye;
25 Claggett, aye; Mukhtar, aye; Roussel,

1 aye.

2 [The motion carried unanimously.]

3 ***

4 Report of Regulatory Counsel

5 [Marc Farrell, Esquire, Regulatory Counsel, Office of
6 Chief Counsel, reported Regulation 16A-5432,
7 Licensure by Endorsement, had been deemed approved by
8 the Independent Regulatory Review Commission (IRRC)
9 on July 16, 2026. The regulation was scheduled to be
10 published as final in the August 29, 2026 edition of
11 the *Pennsylvania Bulletin*.

12 Mr. Farrell noted the Board was provided a
13 revised Annex for Regulation 16A-5427, General
14 Revisions. He reviewed changes made to the Annex
15 based on discussions during the special regulatory
16 meeting held in June 2026.

17 The first change was made in Sections 27.24 and
18 27.25 where the proposed subsection (d) regarding a
19 specific Pennsylvania jurisprudence exam was removed.
20 Additionally, a new subsection (d) was created for
21 27.24. The new language stated, "A candidate
22 enrolled in an ACPE accredited Doctor of Pharmacy
23 program may sit for the MPJE or other Board
24 identified pharmacy jurisprudence examination upon
25 completion of all required didactic coursework.

1 Completion of the professional degree shall be
2 required prior to the issuance of a pharmacist
3 license, but not for the eligibility to sit for the
4 jurisprudence exam." The Board approved the new
5 language.

6 The next change was in section 27.41 where the
7 Department of Welfare was corrected to the Department
8 of Human Services. A typographical change was also
9 noted for section 27.204.

10 Additionally in section 27.204, a new subsection
11 (b)(6) was added to reflect a provision mentioned by
12 Chair Roussel during the June regulatory meeting. He
13 stated the new section reads, "When an automated
14 medication system is used in conjunction with barcode
15 medication administration processes performed by
16 licensed healthcare practitioners, pharmacist
17 verification may be performed at the medication order
18 level. The pharmacist shall ensure the clinical
19 appropriateness of the order, while the accuracy of
20 the product selection and stocking may be verified
21 through validated automated medication systems
22 procedures and institutional quality programs." The
23 Board approved the new language.

24 Mr. Farrell reviewed the next steps of the
25 package, noting because the package had a long track

1 record of development with the input of the Board and
2 significant stakeholder input, the Preamble and Annex
3 would be reviewed internally before being brought
4 back to the Board for approval.

5 Chair Roussel stated Mr. Farrell had a thoughtful
6 plan and offered her assistance with regards to the
7 Preamble. She questioned the timeline for the
8 package as people were likely eager to take the
9 universal multi-state jurisprudence exam (UMPJE).
10 Mr. Farrell hoped to have the regulation published as
11 proposed before the end of the year; however, there
12 was no way to predict how many comments would be
13 received. If many comments were received, the
14 timeline would be extended; however, if the final
15 package was turned around quickly, there was a chance
16 of publishing the final package by the second quarter
17 of 2027.

18 Jill Rebuck, Executive Director, Pennsylvania
19 Society of Health-System Pharmacists, asked if paper
20 copies could be presented at meetings in the future
21 for stakeholders to see the changes prior to the
22 discussions. Mr. Barrett noted there would also be
23 more notice and comment during the regulatory
24 process. Mr. Farrell stated Mr. Barret was correct
25 and appreciated Ms. Rebuck's comments.

1 Chair Roussel asked if there was a scope of
2 volume of comments which would require the Board to
3 take a step back in the process. Mr. Farrell stated
4 typically things can be removed or added up to a
5 certain point provided the scope of the proposed
6 rulemaking was not expanded. Mr. Barrett noted
7 contested regulations with a lot of community
8 pushback, but he did not expect the same with the
9 general revisions due to the Board using a very open
10 and collaborative process.

11 Chair Roussel next asked if IRRC liked it when
12 people commented that they liked the regulation or if
13 less comments were better. Mr. Farrell replied
14 supportive comments were welcomed; however,
15 unsupportive comments were also welcomed.

16 Victoria Elliott, R.Ph., CEO, Pennsylvania
17 Pharmacists Association, noted PPA was not at the
18 June 2026 meeting. She asked for additional
19 clarification surrounding the exam language. It was
20 summarized that the language required a jurisprudence
21 exam, either the MPJE or another Board approved exam,
22 and allow students to take the exam after the
23 completion of didactic coursework. Additionally, it
24 was noted the language granted the Board flexibility
25 if the exam changed in the future without requiring

1 new regulations to be passed.

2 Jonathan Ference, Pharm.D., Dean, Nesbitt School
3 of Pharmacy, Wilkes University, asked if the Board
4 could provide a timeline on when a decision would be
5 made on what exam would be approved so schools could
6 prepare the proper curriculum. Mr. Barrett cautioned
7 against giving any timeline due to the length of the
8 regulatory process as well as potential National
9 Association of Boards of Pharmacy (NABP) requirements
10 if the Board chose to use the UMPJE. Dr. Ference
11 rephrased his question, asking what he should tell
12 instructors who may be building out the next five
13 years of curriculum. Chair Roussel replied NABP has
14 curriculum of various jurisprudence exams on their
15 website. Mr. Barrett reiterated the Board could not
16 give a timeline as the regulation had yet to be
17 promulgated. Chair Roussel added, even though the
18 UMPJE does not have state-specific questions, it
19 would still be prudent to teach students about
20 Pennsylvania law.

21 Ms. Rebuck asked, if the regulation was
22 promulgated as presented without major context
23 changes, would the Board be able to vote on specific
24 exams at a meeting without additional layers of
25 approval. Mr. Barrett stated the Board would not

1 need to go through the process of another regulation;
2 however, there would likely be contractual approvals
3 needed through NABP.

4 Regarding Regulation 16A-5435, Opioid Education,
5 Mr. Barrett noted his continuing work on the Annex
6 and hoped to have it prepared for the October 2026
7 meeting. He noted one additional comment was
8 received at the end of the 30-day comment period that
9 was provided to the Board. He planned to work
10 through the comments during the October 2026
11 meeting.]

12 ***

13 Report of Board Chairperson
14 [Christine Roussel, Pharm.D., BCOP, BCSCP,
15 Chairperson, announced, similar to the Board's work
16 during the meetings, there are committees who work
17 between meetings to make sure procedures are
18 expediated. She stated Jim Reed would be added to
19 the Facilities Review Committee.

20 Chair Roussel shared the Food and Drug
21 Administration (FDA) held a meeting on July 23 and
22 24, 2026 related to the compounding of peptides. She
23 strongly recommended anyone compounding using active
24 pharmaceutical ingredients (API) always refer to the
25 most recent FDA guidance.]

Report of Acting Commissioner

[Arion R. Claggett, Acting Commissioner of Professional and Occupational Affairs, requested the Applications Committee be added to the Agenda for the next meeting.]

Report of Executive Secretary

[Sara Trimmer, Pharm.D., R.Ph., Executive Secretary, reported with the pharmacy technician registrations complete, procedures have gotten back to a new normal. She was still receiving pharmacy technician registrations. With a significantly lower volume, processing time is approximately two business days. In addition, pharmacist renewals were at about 40 percent with just under one month since the renewal opened. When asked, she also shared there were over 26,000 pharmacy technicians registered and about 25,000 pharmacists in the state.]

Report of Board Members - No Report

Review of Applications

MR. BARRETT:

Based on Executive Session

1 deliberations, I believe the Board
2 Chair would entertain a motion to
3 approve the pharmacy technician
4 application at No. 16 of David Barker.

5 ACTING COMMISSIONER CLAGGETT:

6 Claggett, so moved.

7 MR. REED:

8 Reed, second.

9 CHAIR ROUSSEL:

10 All right. Any further discussion?

11 Let's call the vote.

12

13 Reed, aye; Hart, aye; Esterbrook, aye;
14 Claggett, aye; Mukhtar, aye; Roussel,
15 aye.

16 [The motion carried unanimously.]

17 ***

18 MR. BARRETT:

19 Based on Executive Session
20 deliberations, I believe the Board
21 Chair would entertain a motion to
22 provisionally deny the pharmacy
23 technician or pharmacy technician
24 trainee applications of Item No. 17,
25 Jodi Ettinger; No. 18, Aleshia Gardner;

1 No. 19, Jacob Keim; No. 20, Jameer
2 Jackson; No. 21, Danita Jones; and No.
3 22, Erica Montgomery.

4 CHAIR ROUSSEL:

5 Please make any motions.

6 ACTING COMMISSIONER CLAGGETT:

7 Claggett, so moved.

8 MR. REED:

9 Reed, second.

10 CHAIR ROUSSEL:

11 Any further discussion? We'll call the
12 vote.

13

14 Reed, aye; Hart, aye; Esterbrook, aye;
15 Claggett, aye; Mukhtar, aye; Roussel,
16 aye.

17 [The motion carried unanimously.]

18 ***

19 Discussion - Competent Authorities under 49 PA Code
20 27.403(e)

21 [Sean C. Barrett, Esquire, Board Counsel, noted one
22 year ago, the Board approved other competent
23 authorities under 49 PA Code 27.403(e). The approved
24 authorities were the American College of
25 Obstetricians (ACOG), American Academy of Pediatrics

1 (AAP), American Academy of Family Physicians (AAFP),
2 and FDA. He stated it was time to vote on if the
3 Board wanted to continue to approve those
4 organizations as competent authorities.]

5 CHAIR ROUSSEL:

6 I think considering the fact that the
7 Department of Health just announced
8 today that two individuals who are
9 unvaccinated for measles have died of
10 the disease really, I think, supports
11 the importance that we take action for,
12 you know, competent authorities related
13 to vaccines.

14 So I would entertain a motion.

15 MR. BARRETT:

16 And I just guess for the Board Members
17 knowledge and how familiar you are, but
18 there's the pending litigation with AAP
19 *versus Kennedy* which is relating to the
20 ACIP schedules that are kind of in
21 flux. There was a hold placed on or a
22 stay granted that stayed the most
23 recent attempt of guidelines. So there
24 is some uncertainty. But my
25 understanding is that approving these

1 competent authorities will go a long
2 way to ensuring vaccine access in
3 pharmacies.

4 ACTING COMMISSIONER CLAGGETT:

5 And with that, Claggett so moved.

6 MR. REED:

7 Reed, second.

8 CHAIR ROUSSEL:

9 Any further discussion? We'll call the
10 vote.

11

12 Reed, aye; Hart, aye; Esterbrook, aye;
13 Claggett, aye; Mukhtar, aye; Roussel,
14 aye.

15 [The motion carried unanimously.]

16

17 Discussion - BEI Inspection Reports Question Changes

18 [Christine Roussel, Pharm.D., BCOP, BCSCP,

19 Chairperson, explained Pennsylvania has an inspection

20 form that does not specifically call out that a

21 pharmacy has been inspected for non-sterile, sterile,

22 or hazardous drug compounding. She noted inspectors

23 do a thoughtful job and do inspect for compounding;

24 however, there was the matter of documentation. She

25 added, due to the lack of documentation, pharmacies

1 and pharmacists from Pennsylvania are required to get
2 third-party inspections to satisfy regulators from
3 other states.

4 Mr. Barrett pointed out the questions and changes
5 to the inspection report were proposed by the Bureau
6 of Enforcement and Investigations (BEI). He stated
7 the Board needed to decided if it wanted to approve
8 the questions or make any changes.

9 Chair Roussel reviewed the proposed questions for
10 the attendees. The Board discussed the language
11 used. It was noted in the first part of each
12 question the word "preparation" could be removed.

13 Jill Rebuck, Executive Director, Pennsylvania
14 Society of Health-System Pharmacists, asked what
15 stakeholders could expect as to when the changes
16 would be finalized and utilized by inspectors. Mr.
17 Barrett could not give a good estimate due to system
18 updates. Ms. Rebuck asked if it was correct to
19 presume the changes were operationally related and,
20 at some point, would be updated with no additional
21 needed approvals. Acting Commissioner Claggett
22 responded, after the Board voted on it, no additional
23 approvals were needed.

24 Chair Roussel pointed out pharmacies were already
25 being subjected to the inspection questions, so there

1 would be no change in practice or inspections. The
2 only change would be to documentation on the form, so
3 it could be better sent to other state regulators.]

4 MR. BARRETT:

5 So I think, based on discussions here,
6 I believe the Board Chair would
7 entertain a motion to adopt the
8 proposed additions to the pharmacy
9 inspection questions, subject to the
10 amendments that we've discussed.

11 ACTING COMMISSIONER CLAGGETT:

12 Claggett, so moved.

13 MR. REED:

14 Reed, second.

15 CHAIR ROUSSEL:

16 Okay. Any further discussion? Call
17 the vote.

18
19 Reed, aye; Hart, aye; Esterbrook, aye;
20 Claggett, aye; Mukhtar, aye; Roussel,
21 aye.

22 [The motion carried unanimously.]

23 ***

24 Discussion - Annual NABP District 1 and 2 Meeting
25 [Christine Roussel, Pharm.D., BCOP, BCSCP,

1 Chairperson, explained the Annual NABP meeting would
2 be happening in Connecticut. She was currently on
3 the resolutions committee for the national meeting in
4 May 2027, so it would be prudent for her to attend
5 the district meeting. The Board briefly discussed
6 possible attendees.]

7 CHAIR ROUSSEL:

8 Okay. So I would entertain a motion if
9 somebody would like to make a motion.

10 MR. ESTERBROOK:

11 I'll make a motion to send three people
12 to the District 1 and 2 meeting in
13 October.

14 ACTING COMMISSIONER CLAGGETT:

15 Claggett, second.

16 CHAIR ROUSSEL:

17 Okay. Any further discussion? We'll
18 call the vote.

19

20 Reed, aye; Hart, aye; Esterbrook, aye;
21 Claggett, aye; Mukhtar, aye; Roussel,
22 aye.

23 [The motion carried unanimously.]

24

25 [Chair Roussel noted resolutions could be proposed in

1 two forms, either from a state or by an individual.
2 She shared her intention to submit a resolution. The
3 resolution would request NABP put together a
4 committee to focus on improving drug interaction
5 checking with cannabis products. She noted, because
6 cannabis is not a formal drug by USP (United States
7 Pharmacopeia), any drug interactions for THC and CBS
8 do not pop up related to retail drugs.]

9 ***

10 Discussion - Board meeting at another PA College of
11 Pharmacy

12 [Christine Roussel, Pharm.D., BCOP, BCSCP,
13 Chairperson, stated the meeting held at Wilkes
14 University was lovely with a packed room of students.
15 Mr. Esterbrook suggested the next off-site meeting be
16 held on the western side of the state, perhaps at one
17 of the Pittsburgh pharmacy schools. Chair Roussel
18 agreed with Mr. Esterbrook, noting before setting a
19 date, it would helpful to pursue schools interested
20 in hosting the Board.

21 Jill Rebuck, Executive Director, Pennsylvania
22 Society of Health-System Pharmacists, shared she was
23 meeting with the deans of the pharmacy schools at
24 both Duquesne University and University of
25 Pittsburgh. She offered to ask in person and let Ms.

1 Trimmer know of any interest.

2 The Board discussed when the appropriate time of
3 year would be for the meeting, noting travel in the
4 winter might be difficult. Mr. Barrett suggested
5 waiting until the October meeting to discuss
6 specifics. Chair Roussel noted the meetings would be
7 in Harrisburg until otherwise announced.]

8 ***

9 Discussion - Pharmacy Technician Registration

10 [Sean C. Barrett, Esquire, Board Counsel, stated
11 moving forward the pharmacy technician registration
12 would not be a standing Agenda item; however, he
13 asked if there were any thoughts from the community
14 regarding the application process or any impediments.
15 He noted, with processing over 26,000 applications,
16 most of the kinks had been worked out.

17 Jill Rebuck, Executive Director, Pennsylvania
18 Society of Health-System Pharmacists, commented a
19 standing discussion did not need to continue. She
20 referred to the earlier review of applications,
21 asking if there were any general themes that
22 stakeholders could be made aware of as far as reasons
23 for denials. Mr. Barrett could not speak to specific
24 applications; however, there had been a number of Act
25 53 convictions that prohibit the Board from granting

1 a license. He added all of the denials were
2 provisional denials, giving the applicants the
3 opportunity for a hearing and for the Board to change
4 their decision. He also noted another common denial
5 reason is prior discipline from a different license.
6 He commented there had not been many denials due to
7 education issues.

8 Ms. Rebuck next asked if the Board could clarify
9 if pharmacists in Pennsylvania who do not practice in
10 a dispensing setting need to have PDMP registration.
11 Mr. Barrett replied the Board could not answer the
12 question as the answer may potentially be legal or
13 advisory.

14 Ms. Rebuck asked whether it would be recommended
15 that all pharmacists, regardless of their role,
16 should register. She added Ms. Trimmer received the
17 question as several people posed the question to Ms.
18 Rebuck. Ms. Trimmer received many emails and the
19 question was an informational regulatory question
20 that had to be asked and did not preclude a license
21 from being renewed. Ms. Rebuck provided additional
22 background on why the question was being asked,
23 noting a future FAQ or guidance from the Board may be
24 helpful.

25 Mr. Barrett noted quick research showed a

1 pharmacist fact sheet from 2017 issued from the
2 Department of Health stated all licensed prescribers
3 and pharmacists in Pennsylvania are required to
4 register with PDMP. He had not examined the factual
5 background or if the requirement was still current.]

6 ***

7 CHAIR ROUSSEL:

8 Do we need a motion to reenter
9 Executive Session?

10 MR. BARRETT:

11 Yes. So based on discussions here and
12 with the consideration of the
13 presentation of Prosecution, dose any
14 Member of the Board wish to enter
15 Executive Session?

16 MR. ESTERBROOK:

17 Yes, Esterbrook.

18 MR. BARRETT:

19 Okay. So based on that, I believe the
20 Board Chair would entertain a motion to
21 reenter Executive Session.

22 ACTING COMMISSIONER CLAGGET:

23 Claggett, so moved.

24 MR. REED:

25 Reed, second.

1 CHAIR ROUSSEL:

2 Okay. Any further discussion? Call
3 the vote.

4

5 Reed, aye; Hart, aye; Esterbrook, aye;
6 Claggett, aye; Mukhtar, aye; Roussel,
7 aye.

8 [The motion carried unanimously.]

9

10 [Pursuant to Section 708(a)(5) of the Sunshine Act,
11 at 12:25 p.m., the Board entered into Executive
12 Session with Sean C. Barrett, Esquire, Board Counsel,
13 for the purpose of conducting quasi-judicial
14 deliberations and to receive the advice of Board
15 Counsel. The Board returned to open session at 12:42
16 p.m.]

17

18 Report of Prosecution Motions

19 MR. BARRETT:

20 Based on Executive Session
21 deliberations, I believe the Board
22 Chair would entertain a motion to
23 reject as too lenient the Consent
24 Agreements at Item No. 6, Case No. 23-
25 54-015900; and Item No. 7, Case No. 25-

1 54-009263.

2 CHAIR ROUSSEL:

3 Do I have a motion?

4 ACTING COMMISSIONER CLAGGETT:

5 Claggett, so moved.

6 MR. REED:

7 Reed, second.

8 CHAIR ROUSSEL:

9 Any discussion? Call the vote.

10

11 Reed, aye; Hart, aye; Esterbrook, aye;

12 Claggett, aye; Mukhtar, aye; Roussel,

13 aye.

14 [The motion carried unanimously.]

15 ***

16 MR. BARRETT:

17 Based on Executive Session

18 deliberations and the Report of

19 Prosecution, at Item No. 8, Case No.

20 25-54-015364, I believe the Board Chair

21 would entertain a motion to reject the

22 Consent Agreement as too lenient. I

23 will note for the record that Board

24 Member Esterbrook did recuse himself

25 from any discussion in this matter.

1 CHAIR ROUSSEL:

2 Do I have a motion?

3 ACTING COMMISSIONER CLAGGETT:

4 Claggett, so moved.

5 MR. REED:

6 Reed, second.

7 CHAIR ROUSSEL:

8 Any discussion? Call the vote.

9

10 Reed, aye; Hart, aye; Esterbrook,
11 recuse; Claggett, aye; Mukhtar, aye;
12 Roussel, aye.

13 [The motion carried. Mr. Esterbrook was recused from
14 deliberations and voting on the motion.]

15 ***

16 MR. BARRETT:

17 And then at Item No. 9, Case No. 26-54-
18 000752 and Case No. 26-54-001677, based
19 on Executive Session deliberations and
20 the Report of Prosecution, I believe
21 the Board Chair would entertain a
22 motion to approve the Consent Agreement
23 at these numbers. And I will note for
24 the record, Board Members Reed and
25 Esterbrook did recuse themselves from

1 deliberation on these matters.

2 CHAIR ROUSSEL:

3 Do I have a motion?

4 ACTING COMMISSIONER CLAGGETT:

5 Claggett, so moved.

6 MS. HART:

7 Hart, second.

8 CHAIR ROUSSEL:

9 Any further discussion? Call the vote.

10

11 Reed, recuse; Hart, aye; Esterbrook,

12 recuse; Claggett, aye; Mukhtar, aye;

13 Roussel, aye.

14 [The motion carried. Mr. Reed and Mr. Esterbrook
15 were recused from deliberations and voting on the
16 motion. The Respondent at Agenda Item No. 9, Case
17 Nos. 26-54-000752 and 26-54-001677, is Nathan J Bear,
18 RPh.]

19 ***

20 Public Comment - None

21 ***

22 Adjournment

23 CHAIR ROUSSEL:

24 Any further discussions? All right. I
25 would entertain a motion to adjourn.

1 ACTING COMMISSIONER CLAGGETT:

2 Claggett, so moved.

3 MR. REED:

4 Reed, second.

5 CHAIR ROUSSEL:

6 All right. I don't think we have to
7 call the vote. We can just adjourn.
8 This was a great meeting guys, way
9 productive.

10 ***

11 [There being no further business, the State Board of
12 Pharmacy Meeting adjourned at 12:45 p.m.]

13 ***

14

15

16

17

18

19

20

21

22


23

24

25

CERTIFICATE

I hereby certify that the foregoing summary minutes of the State Board of Pharmacy meeting, was reduced to writing by me or under my supervision and the minutes accurately summarize the substance of the State Board of Pharmacy meeting.

A handwritten signature in cursive script, reading "Laurie Elliott", is written over a horizontal line.

Laurie Elliott,

Minute Clerk

Sargent's Court Reporting
Service, Inc.

STATE BOARD OF PHARMACY
REFERENCE INDEX
August 25, 2026

TIME	AGENDA
9:00	Executive Session
10:30	Return to Open Session
10:32	Official Call to Order
10:33	Introduction of Board Members/Attendees
10:36	Approval of Minutes
10:37	Report of Prosecution
10:42	Appointment - Survey of Pharmacists' Experience with Buprenorphine Dispensing Policies
11:14	Report of Prosecution (cont.)
11:31	Report of Board Counsel
11:32	Report of Regulatory Counsel
11:57	Report of Board Chairperson
11:58	Report of Acting Commissioner
11:59	Report of Executive Secretary
12:00	Review of Applications
12:01	Discussion
12:25	Executive Session
12:42	Return to Open Session
12:42	Report of Prosecution Motions
12:45	Adjournment